# US 2021/0069265 A1 · Pediococcus Pentosaceus CCFM1012 and Application thereof to Preparation of Campylobacter Jejuni Infection Antagonism Medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069265 A1
- Document ID: US20210069265A1
- Status: Published application
- Kind: A1
- Application number: 17/019,867
- Filed: 2020-09-14
- Published: 2021-03-11
- Earliest claimed: 2018-03-15
- Assignees: Jiangnan University
- Applicants: Jiangnan University
- Inventors: Gang WANG; Wei CHEN; Xing JIN; Jianxin ZHAO; Hao ZHANG
- Web page: https://patentgrep.com/patent/US20210069265A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A23K 10/18: of live microorganisms
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 47/02: Inorganic compounds
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 31/04: Antibacterial agents
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- A61K 2035/115: {Probiotics}
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The disclosure discloses P. pentosaceus CCFM1012, fermented food thereof and application thereof to preparation of a C. jejuni infection antagonism medicine. The P. pentosaceus CCFM1012 of the disclosure can remarkably reduce a colonization rate of in-vivo C. jejuni of mice infected with C. jejuni and transcriptional activity of virulence genes flaA, cadF, cdtB, cdtC and dnaJ of the C. jejuni, can effectively relieve physiological damage caused by infection of the C. jejuni, can also be used for preparing dairy products, bean products and fruit and vegetable fruits for preventing infection of the C. jejuni and an additive that can be added to a poultry and livestock feed for reducing infection and carrying of the C. jejuni in poultry and livestock, and has quite broad application prospects.

## Claims

### Claim 1

A composition comprising Pediococcus pentosaceus (P. pentosaceus) CCFM1012, wherein the P. pentosaceus CCFM1012 was deposited on Feb. 11, 2018 at the Guangdong Microbial Culture Collection Center, Guangdong Institute of Microbiology, 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, with preservation number of GDMCC No. 60331.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the composition is a fermented food prepared by fermenting the P. pentosaceus CCFM1012; the fermented food comprises dairy products, bean products and fruit and vegetable products; the dairy products comprise milk, sour cream and cheese; and the fruit and vegetable products comprise cucumber, carrot, beet, celery and cabbage products.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the composition is a microbial preparation.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the microbial preparation is a cell culture fluid of the P. pentosaceus CCFM1012.

### Claim 5 (depends on 4)

The composition according to claim 4, wherein the cell culture fluid is a cell culture fluid obtained by culturing the P. pentosaceus CCFM1012 in an MRS medium.

### Claim 6 (depends on 3)

The composition according to claim 3, wherein the P. pentosaceus CCFM1012 has a cell concentration of larger than or equal to 1×107 CFU/mL.

### Claim 7 (depends on 3)

The composition according to claim 3, wherein the microbial preparation is a freeze-dried preparation comprising viable cells of the P. pentosaceus CCFM1012, and is prepared by fermenting the P. pentosaceus CCFM1012 in an MRS medium, collecting bacterial cells, mixing the bacterial cells with a cytoprotective agent and then performing a freeze-drying treatment.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the composition is a feed additive.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the feed additive is a feed additive finished product containing the P. pentosaceus CCFM1012 with a viable count of larger than or equal to 1×1010 CFU/g, and is obtained by mixing bacterial cells of the P. pentosaceus CCFM101 with sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, calcium chloride and water and performing wet granulating and drying.

### Claim 10 (depends on 1)

A method of use of P. pentosaceus CCFM1012 of claim 1, comprising preparing a Campylobacter jejuni infection antagonism medicine.

### Claim 11 (depends on 10)

The method according to claim 10, further comprising:
(1) restraining growth of C. jejuni;
(2) reducing an in-vivo colonization quantity of the C. jejuni;
(3) lowering expression levels of virulence genes flaA, cadF, cdtB, cdtC and dnaJ of the C. jejuni; and
(4) relieving physiological damage caused by infection of the C. jejuni.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the medicine is a liquid, a powder or a granule comprising the P. pentosaceus CCFM1012.
